Topline results from the 52-week open-label trial show the treatment was well tolerated with a safety profile consistent with standard-of-care.
Camurus has shared positive, final, topline results from the ACROINNOVA 2 Phase III clinical trial (NCT04125836). The study evaluated the safety and efficacy of Camurus’ once-monthly octreotide subcutaneous (SC) depot, CAM2029 in patients with acromegaly.1
Overall, results from the trial indicated that treatment was well tolerated with a safety profile consistent with standard-of-care (SoC), increased biochemical response rates (IGF-1≤1xULN) vs SoC at baseline, and continuous improvement of acromegaly symptom and quality of life scores vs baseline.
The open-label, single-arm, multi-center Phase III trial spanned 52 weeks and included a total of 135 patients with acromegaly who were biochemically controlled (IGF-1≤1xULN) or uncontrolled on stable doses of SoC with first generation somatostatin ligands (SRL) at screening. Of these participants, 81 were new to the study and 54 were roll-over from a 24-week randomized treatment with octreotide SC depot or placebo (ACROINNOVA 1). The primary endpoint was safety over 52 weeks of study treatment with secondary endpoints including biochemical control rates, symptom scores, and several patient-reported outcomes.2
Acromegaly is a hormonal disorder that develops when the pituitary gland produces too much growth hormone during adulthood. This leads to an increase in bone size of the hands, feet, and face. Since the disorder is uncommon and physical changes occur slowly, it often takes a long time to recognize.3
“Today’s results from ACROINNOVA 2 highlight the long-term safety profile and efficacy of octreotide SC depot in patients with acromegaly, including patients with uncontrolled disease on standard-of-care", Fredrik Tiberg, Camurus’ president & CEO, CSO said in a press release. “These data further strengthen the evidence base for CAM2029 octreotide SC depot as a new treatment option for people living with acromegaly, if approved. Regulatory reviews are ongoing in both the US and EU with a first approval decision expected from the US FDA by the PDUFA action date October 21, 2024.”
According to Camurus, octreotide SC depot was well tolerated with a long-term safety profile consistent with that of SoC with first generation SRL, extended-release octreotide and lanreotide, with no new safety signals. Treatment with octreotide SC depot over the 52-week study timeline resulted in significant increases in treatment response rates of 12.7% (95%CI: 5.5%, 19.9%) in the overall population, and 22.8% (95%CI: 11.6, 33.9) in new patients compared SoC at baseline. Additionally, roll-over patients with controlled IGF-1 values at the SoC baseline maintained or regained (for placebo) biochemical control during treatment with octreotide SC depot.
In the press release, Joanna Spencer-Segal, MD, PhD, assistant professor of internal medicine, division of Metabolism, endocrinology and diabetes, University of Michigan, Ann Arbor, Michigan, US, and ACROINNOVA 2 study investigator added: “The results from ACROINNOVA 2 are very encouraging and demonstrated that CAM2029 octreotide SC depot was effective in normalizing IGF-1 levels across patient groups and continuously improving symptoms of acromegaly throughout the 52 weeks of treatment. Additionally, the convenience of a once-monthly SC dosing using the prefilled autoinjector pen contributed to improved treatment satisfaction and quality of life, which are important unmet needs for patients living with acromegaly.”
1. Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients. News release. Camurus. July 15, 2024. Accessed July 16, 2024. https://www.camurus.com/media/press-releases/2024/camurus-announces-positive-phase-3-results-from-the-acroinnova-2-study-of-octreotide-sc-depot-cam2029-in-acromegaly-patients
2. A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly. ClinicalTrials.gov. Accessed July 16, 2024. https://clinicaltrials.gov/study/NCT04125836?tab=history&a=4
3. Acromegaly. Mayo Clinic. February 8, 2024. Accessed July 16, 2024. https://www.mayoclinic.org/diseases-conditions/acromegaly/symptoms-causes/syc-20351222#:~:text=Acromegaly%20is%20a%20hormonal%20disorder,in%20height%20doesn't%20occur.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.